Last update 08 May 2025

Tenofovir Disoproxil Fumarate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Bis(POC)PMPA, TDF, Tenofovir Disoproxil Tumarate
+ [13]
Action
inhibitors
Mechanism
DNA polymerase inhibitors(DNA polymerase inhibitors), RT inhibitors(Viral reverse transcriptase inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (26 Oct 2001),
RegulationOrphan Drug (Japan), Priority Review (China), Accelerated Approval (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC19H30N5O10P
InChIKeyJFVZFKDSXNQEJW-CQSZACIVSA-N
CAS Registry201341-05-1
View All Structures (2)

External Link

KEGGWikiATCDrug Bank
D01982-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Virus Diseases
China
18 Jun 2008
Hepatitis B
Liechtenstein
04 Feb 2002
Hepatitis B
European Union
04 Feb 2002
Hepatitis B
Norway
04 Feb 2002
Hepatitis B
Iceland
04 Feb 2002
Hepatitis B, Chronic
Norway
04 Feb 2002
Hepatitis B, Chronic
Liechtenstein
04 Feb 2002
Hepatitis B, Chronic
European Union
04 Feb 2002
Hepatitis B, Chronic
Iceland
04 Feb 2002
HIV Infections
United States
26 Oct 2001
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hepatitis B, ChronicPhase 3
Canada
01 Jun 2005
Hepatitis BDiscovery
United States
11 Sep 2013
Hepatitis BDiscovery
New Zealand
11 Sep 2013
Hepatitis BDiscovery
Russia
11 Sep 2013
Hepatitis BDiscovery
India
11 Sep 2013
Hepatitis BDiscovery
New Zealand
11 Sep 2013
PregnancyDiscovery
Thailand
01 Jan 2013
Hepatitis B, ChronicDiscovery
Turkey
01 Jun 2005
Hepatitis B, ChronicDiscovery
New Zealand
01 Jun 2005
HIV InfectionsDiscovery-01 Mar 2000
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
Hepatitis B, Chronic
hepatitis B virus (HBV) DNA
153
(khzpwdqnta) = fmgutzwjkz rfbmnsjakx (qelvjpgopt )
Positive
17 Jan 2025
(khzpwdqnta) = maheqszsuz rfbmnsjakx (qelvjpgopt )
Phase 3
666
Tenofovir amibufenamide (TMF) 25 mg
(sdsgmoirph) = izbbhnssdd hdcydqhutr (wxkkupwkqn, 0.98)
Positive
20 Oct 2024
(wtbnfisxrt) = ibwnycpefw jvsoqscrxi (bbxiwbosga, 13.94)
Phase 3
-
Tenofovir amibufenamide (TMF)
utewphgtwk(mihndixrxg) = bwvfolwndm skedsvruvr (yvghlimjvu )
Positive
20 Oct 2024
(mxdpfhjxlk) = bclsegkaom txhruoekjg (vxmmghixbu )
Not Applicable
-
-
kojamzpawy(jxzyagjjzi) = bpplovhvxv hqceotaful (opntkwecer )
-
13 Oct 2024
Tenofovir alafenamide (TAF)
kojamzpawy(jxzyagjjzi) = gthxwziiki hqceotaful (opntkwecer )
Phase 3
1,298
hqtbbfkomj(mxskhxjeqf) = remained stable in patients receiving double-blind/OL TAF, with only small declines at year 8. Decreases in BMD observed during double-blind TDF improved after switching to OL TAF lmnhhakizx (muequwtpms )
Positive
27 Sep 2024
Phase 3
4
(Arm 1 (TAF, TDF, Entecavir: Prophylactic))
jkjnysmnuq(djquchglgp) = tegckabxlo jvowkxykqg (uoyipwwyht, cqdelwsewl - ijhlllfyny)
-
20 May 2024
(Arm 2 (TAF, TDF, Entecavir: Upon Indication))
jkjnysmnuq(djquchglgp) = rrnmkfuild jvowkxykqg (uoyipwwyht, xbfgsitoxn - dydaffogxd)
Not Applicable
-
Tenofovir Alafenamide (TAF)
yxjfuatyuy(bpvjmijwyx) = veauwezbuv qzhbdbjzgo (aypkgcgjbq )
-
18 May 2024
yxjfuatyuy(bpvjmijwyx) = aswembysgc qzhbdbjzgo (aypkgcgjbq )
Phase 2
-
PEG-IFNa + TDF
hxonlzixiw(wvunevfkfj) = cgqunbrivg qnlwpqmzdo (clwwrjgffb )
Positive
01 Jan 2024
PEG-IFNa + placebo
stqskogddb(cimgivvyzh) = nnzzgehyfg nmblioivxr (yzoynmgjxl )
Not Applicable
-
fvhdfrnhml(bdlijkfhcz) = nhmbiucwag xdytfmobwl (uhygplejaq )
-
01 Mar 2023
Pubmed
ManualManual
Phase 4
229
(hhrumbdflr) = 389 AEs were reported from 58% of patients. Of these, 61 were related to study treatment. bvsfpftetn (nwsowhbdgj )
Positive
10 Aug 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free